Acarbose
Precose / alpha-glucosidase inhibitor
Acarbose (Precose / alpha-glucosidase inhibitor) is a longevity & bioregulators research compound. Inhibits intestinal alpha-glucosidase, slowing the breakdown of complex carbohydrates so glucose enters the blood more gradually. Undigested carbohydrate reaching the colon is also fermented, which is both the mechanism behind the side effects and a plausible route to microbiome effects.
Acarbose quick facts
| Reported research dose | 25mg-100mg with each carb meal |
| Route | Oral |
| Frequency | With each carb meal |
| Half-life | ~2 hrs |
| Forms | Oral |
| Evidence level | Human (diabetes); rodent lifespan data |
One of the few compounds with reproducible lifespan extension in the NIA Interventions Testing Program — notably larger in male mice. In humans it's a modest glucose drug with a very specific downside: substantial flatulence and bloating, which is the mechanism working rather than a side effect to push past. Prescription only.
How Acarbose works
Inhibits intestinal alpha-glucosidase, slowing the breakdown of complex carbohydrates so glucose enters the blood more gradually. Undigested carbohydrate reaching the colon is also fermented, which is both the mechanism behind the side effects and a plausible route to microbiome effects.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Acarbose
Buy Acarbose at AlgoRx →The evidence for Acarbose
Graded by what exists behind each claim.
✅ Clinically validated
- Approved for type 2 diabetes, with trial data showing reduced post-meal glucose and modest HbA1c improvement. The STOP-NIDDM trial reported reduced progression to diabetes in people with impaired glucose tolerance, and a secondary analysis suggested fewer cardiovascular events — though that secondary finding has been criticized.
- The large ACE trial in Chinese patients with coronary disease and prediabetes missed its primary cardiovascular endpoint, while confirming the reduction in progression to diabetes. Two different questions, two different answers.
📊 Correlative data
- The NIA Interventions Testing Program found it extended lifespan in mice, with a notably larger effect in males — which is why a decades-old diabetes drug appears in longevity stacks at all.
- Real-world use is limited by tolerability rather than safety: flatulence and bloating are near-universal at the start and are the reason most people stop.
🧪 Theoretical / extrapolated
- Inhibits alpha-glucosidase in the small intestine brush border, slowing the breakdown of complex carbohydrates into absorbable glucose. It does not block absorption — it delays and flattens it.
- The side effect is the mechanism, not a separate problem: undigested carbohydrate reaching the colon is fermented by bacteria, which produces the gas. That also means it functions as an inadvertent prebiotic, raising short-chain fatty acid production — one proposed explanation for the mouse lifespan result.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Acarbose actually does
Acarbose is the only compound in this Vault whose site of action is the inside of the intestine, not the inside of a cell. It is a pseudotetrasaccharide — a molecule built to look like a starch fragment — and it works by being a substrate the enzyme cannot finish.
The enzyme, precisely. Dietary starch is cut by salivary and pancreatic alpha-amylase into oligosaccharides, and those are cut into glucose by the alpha-glucosidases anchored in the brush border of the small intestine: sucrase-isomaltase and maltase-glucoamylase. Acarbose binds the catalytic site of these brush-border enzymes with far higher affinity than the real substrate and is hydrolyzed extremely slowly. It is a competitive, reversible inhibitor that occupies the active site for a long time, which is why it has to be present in the lumen at the same moment the carbohydrate is.
What that does to the glucose curve, and why it is a shape change rather than a size change. Blocking the final cleavage step does not stop carbohydrate absorption; it moves it distally and spreads it out. Glucose that would have entered across the jejunum in twenty minutes enters across a longer stretch of intestine over a longer period. The postprandial peak flattens. This is why acarbose lowers post-meal glucose far more than it lowers fasting glucose, and why the trial literature reports a modest HbA1c change beside a large excursion change Zamani 2023.
The consequence that is a side effect and a mechanism at the same time. Carbohydrate that reaches the colon undigested is fermented by the microbiota into short-chain fatty acids and gas. The gas is the flatulence and bloating that defines the drug's tolerability. The short-chain fatty acids are a signal: colonic propionate and butyrate stimulate enteroendocrine L-cells to release GLP-1, which is a proposed route by which acarbose could produce metabolic effects beyond the glucose curve McCarty 2015. The same undigested starch produces the complaint and the hypothesis.
And a pharmacokinetic fact that follows from all of it: acarbose is barely absorbed. Systemic exposure to intact drug is a few percent of the dose. A drug that does not enter the circulation cannot have a systemic mechanism, which constrains every extrapolation on this page to something that starts in the lumen.
Cell, rodent, human — and where it stops
Step one, enzymology: settled and old. Brush-border alpha-glucosidase inhibition is textbook biochemistry and the reason acarbose was approved in the first place.
Step two, humans, pooled. A systematic review and dose-response meta-analysis of acarbose in impaired glucose tolerance and diabetes reports a weighted mean difference in fasting blood glucose of −3.55 mg/dL (95% CI −6.29 to −0.81; p = 0.011) and in HbA1c of −0.32% (95% CI −0.45 to −0.20; p < 0.001) Zamani 2023. Look at the size of those numbers honestly. A third of a point of HbA1c is a real but small effect, and 3.55 mg/dL of fasting glucose is almost nothing — exactly what the mechanism predicts, because fasting glucose is not made of breakfast.
Step three, the endpoint the mechanism actually predicts. A 2025 trial compared glucose fluctuation on metformin plus acarbose against metformin plus sitagliptin in Chinese patients with type 2 diabetes Cai 2025. Variability, not average, is the measurement that matches a drug that flattens peaks — and it is the endpoint HbA1c is worst at seeing, because a mean can be identical whether the curve is flat or spiky.
Step four, the longevity claim, and it is a mouse claim. The Interventions Testing Program — the multi-site program that tests candidate longevity drugs in genetically heterogeneous UM-HET3 mice — reported lifespan benefits for rapamycin plus acarbose started at 9 months, with the effect in males Strong 2022. That is a mouse result, in a combination, with a sex difference, and every one of those three qualifiers matters more than the headline.
Where the chain breaks, one at a time. (1) The ITP result is in mice fed a chow diet that is far more starch-dependent than a human one, and acarbose's mechanism is entirely a function of what is in the lumen — so the species difference here is a diet difference, which is a much harder obstacle than usual. (2) The male specificity has never been explained. (3) The GLP-1-via-fermentation hypothesis McCarty 2015 DiNicolantonio 2015 is a proposed route, and the review venue is a cardiology journal rather than a trial. (4) Human cardiovascular outcome data for acarbose is a long-standing argument in the literature rather than a settled result DiNicolantonio 2015, and this page will not report it as settled.
What would have to be true, and how you would know it was not
Three predictions. The first is the one a continuous glucose monitor answers in a fortnight, and the third cuts against the drug.
1. If the enzyme is being inhibited, the excursion flattens and the average barely moves. That is the sharpest testable consequence of the mechanism, and it is what distinguishes acarbose from every other glucose drug. HbA1c at baseline and 12 weeks should move only slightly — a pooled −0.32% is what the literature reports Zamani 2023 — while post-meal excursion should fall substantially. A person who judges acarbose on HbA1c alone will conclude it does nothing, which is the wrong conclusion drawn from the right number.
2. If nothing changes at all, the failure is mechanical, not pharmacological. The drug must be in the lumen with the carbohydrate. Taken away from food it has nothing to inhibit. So the falsification is specific: if excursions are unchanged and there is no flatulence either, the drug is not meeting the substrate — because the gas is the proof that undigested carbohydrate is reaching the colon. The side effect is the assay.
3. The prediction that argues against it: the liver. Elevations in transaminases have been reported with alpha-glucosidase inhibitors, more often at higher doses. A CMP with ALT and AST at baseline and at 12 weeks is the check, and it is a real one rather than a formality. A CBC at the same points is worth having because chronic carbohydrate malabsorption with an altered colonic environment is not a neutral state for micronutrient handling.
What nobody has tested yet
Four experiments nobody has run, and the first is the one this whole page is waiting on.
Nobody has tested acarbose alone for lifespan in humans, or even for a validated aging surrogate. The mouse result is a combination with rapamycin Strong 2022. A human trial with acarbose alone and a defined aging-related endpoint has never been run, and the mechanism gives no reason to expect a starch-inhibitor's mouse effect to survive a diet with a different macronutrient composition.
Nobody has explained the male-specific effect. Sex-specific responses to longevity interventions are a documented pattern rather than a fluke Bartke 2023. For acarbose specifically, nobody has published the mechanism, and until somebody does, half the population is extrapolating from a result that was not observed in them.
Nobody has measured the microbiome shift alongside the metabolic effect in the same people. The fermentation hypothesis McCarty 2015 predicts that acarbose's non-glycemic effects track short-chain fatty acid production. A trial measuring fecal and circulating short-chain fatty acids, GLP-1 and glucose excursion in the same participants would confirm or kill the hypothesis in one study, and would also explain why the drug's tolerability varies so much between people with different microbiota.
Nobody has run the adaptation study. Colonic microbiota adapt to a chronic substrate load, which is the everyday observation that flatulence eases after several weeks. If the gas is the assay, does the benefit fade with it? A trial measuring glucose excursion at week 2, week 12 and month 12 on unchanged dose would answer whether the adaptation is only in the symptom or in the effect as well. It is a cheap study and it has not been done.
Acarbose — its own safety story, not its class's
Acarbose is an approved prescription medicine whose entire pharmacology happens in the intestinal lumen, and that makes its risk profile unusual enough that the class block above does not apply.
The dominant adverse effect is gas, and it is the mechanism working. Flatulence, bloating, abdominal discomfort and loose stool come from colonic fermentation of carbohydrate that was not cleaved in the small intestine. It is dose-related, it is the commonest reason people stop, and it is not a sign of harm.
The hypoglycemia rule is specific and counterintuitive, and getting it wrong is dangerous. Acarbose alone does not cause hypoglycemia. Combined with a sulfonylurea or insulin it can. And if hypoglycemia occurs, ordinary table sugar does not work — sucrose is a disaccharide, and the enzyme that would split it is the enzyme acarbose is inhibiting. The correction has to be glucose (dextrose) itself. That is the single most important practical fact about this drug and it is the one most often missing from consumer pages.
Liver enzymes are a real monitoring item, not a formality; see the predictions section, where the test sits with the rest of the falsifiable content.
Who it is wrong for. Inflammatory bowel disease, existing partial intestinal obstruction, conditions in which increased gas formation would be harmful, and significant renal impairment. Those are contraindications from the mechanism rather than from a list: a drug whose action is to deliver fermentable substrate to the colon is the wrong drug for a colon that is already inflamed.
What this page will not do. Recommend a dose or present acarbose as a longevity intervention. The mouse lifespan result is a combination result in one sex Strong 2022; the human evidence is a third of a point of HbA1c Zamani 2023; and stating both together is the whole of what is honestly known.
Sources read for this page
- Zamani M, et al. The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose-response meta-analysis. Frontiers in Nutrition 2023 · PMID 37599681
- Strong R, et al. Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice. Aging Cell 2022 · PMID 36179270
- Cai X, et al. Comparison of glucose fluctuation between metformin combined with acarbose or sitagliptin in Chinese patients with type 2 diabetes. Chinese Medical Journal 2025 · PMID 40178116
- McCarty MF, et al. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart 2015 · PMID 25685364
- DiNicolantonio JJ, et al. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2015 · PMID 26512331
Acarbose — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Inhibiting intestinal alpha-glucosidase slows the breakdown of complex carbohydrate so glucose arrives in the blood more gradually. The predictable consequence is that undigested carbohydrate reaches the colon and is fermented — which is simultaneously the mechanism behind the side effects and the plausible route to any microbiome effect.
- That means the flatulence and bloating are not a tolerability nuisance sitting beside the mechanism. They are the mechanism. A dose with no GI effect at all is a dose that is probably not doing much.
What has actually been reported
- Flatulence, bloating and loose stools in a large fraction of users, worst in the first weeks and worst on high-carbohydrate meals. It attenuates with time and with dose titration.
- Rare transaminase elevations at higher doses.
- It is among the small number of interventions that extended lifespan in the NIA Interventions Testing Program, with a larger effect in male mice than female.
How to reduce the risk
Same mechanism as the prediction.
- Titrate up slowly and take it with the first bite of the meal. Almost all of the intolerance comes from starting at a full dose.
- The GI effects scale with the carbohydrate in the meal, so the meals that make it uncomfortable are the meals it is working on.
- Keep glucose tablets, not sweets, if you are also on a hypoglycemia-capable drug.
What it does to your bloodwork
A fact about the assay.
- Post-prandial glucose is where this acts, so a fasting glucose alone will under-read the effect. Continuous glucose monitoring or a post-meal reading shows it; HbA1c shows it over months.
- ALT/AST at higher doses.
What it overlaps with
- With insulin or a sulfonylurea it adds to hypoglycemia risk — and there is a specific trap: treat that hypoglycemia with glucose, not sucrose, because the drug is blocking sucrose breakdown.
Don't run this if
- Inflammatory bowel disease, significant intestinal obstruction or predisposition to it, or chronic disorders of digestion and absorption.
- Cirrhosis.
The honest unknown
- Whether the rodent lifespan effect translates, and whether it depends on the carbohydrate load it is acting on — which would make it a poor fit for someone already eating low-carbohydrate, since there would be little for it to slow.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Acarbose — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Acarbose moves on your bloodwork
Expected direction, not a measured one.
- TSH (Thyroid-Stimulating Hormone) — ↓ expected to fall
Exogenous thyroid hormone or a thyromimetic suppresses TSH by feedback. A suppressed TSH here is the expected consequence, not evidence of thyroid disease.
What to do: TSH alone is uninterpretable on these. Run free T3 and free T4 with it or the panel means nothing. - Free T3 (Triiodothyronine) — ↑ expected to rise
Rises with dosing, and this is the number driving both the benefit and the risk.
What to do: The gap between 'metabolically effective' and 'losing muscle and beating up your heart' is narrow. Test, don't estimate. - Complete Blood Count (CBC) with Differential — ◆ worth watching
Not the marker itself — but resting heart rate and blood pressure are the real-time readouts of over-dosing here, and they move before any lab does.
What to do: Take a resting heart rate every morning. It is a better early signal than a quarterly panel. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Uncouplers and strong thermogenics raise metabolic demand and can stress liver enzymes.
What to do: Baseline liver function before, and again at 8 weeks.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Acarbose in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Acarbose
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Acarbose — frequently asked questions
What is Acarbose?
Acarbose (Precose / alpha-glucosidase inhibitor) is a longevity & bioregulators research compound. Inhibits intestinal alpha-glucosidase, slowing the breakdown of complex carbohydrates so glucose enters the blood more gradually. Undigested carbohydrate reaching the colon is also fermented, which is both the mechanism behind the side effects and a plausible route to microbiome effects.
Is the full Acarbose protocol on this page?
The reported research dose is on this page, along with how Acarbose works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Acarbose?
Acarbose has an approximate half-life of ~2 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Acarbose?
Current evidence level: Human (diabetes); rodent lifespan data. Acarbose is offered for research purposes only and is not an approved medicine.
Acarbose inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What Acarbose is used for
Acarbose appears under 3 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Acarbose is the insulin-sensitivity arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.